Ƶ

Farxiga OK'd for Kids; Semaglutide Price Hearing; Maintaining GLP-1 Weight Loss

— News and commentary from the endocrinology world

Ƶ MedicalToday
Endo Break over a computer rendering of a man with illustrated body organs.

The FDA approved dapagliflozin (Farxiga) ages 10 years and older with type 2 diabetes, based on results from the phase III T2NOW trial, AstraZeneca announced.

Novo Nordisk's CEO agreed to in a hearing on the price of semaglutide (Ozempic, Wegovy). (Reuters)

didn't change much after banning Tony the Tiger and other cartoon characters on sugary foods. (STAT)

"It is crucial to diagnose and treat diabetic patients who have as early as possible to prevent further complications and optimize outcomes," said authors of a Frontiers in Endocrinology case report.

People who lost at least 40 lbs with the GLP-1 receptor agonists semaglutide and liraglutide (Saxenda) were more likely to a year after treatment discontinuation compared with those who lost less weight, data in Epic Research indicated.

Democrats blocked a GOP bill that would take away states' Medicaid funding if they , arguing that the bill does not go far enough to protect IVF access. (The Hill)

In pregnant women with type 2 diabetes, continuing metformin and was tied to little to no increased risk for non-live birth compared with switching to insulin monotherapy. (Annals of Internal Medicine)

Intensive glucose control was not associated with in critically ill adults, but was linked to an increased risk of severe hypoglycemia. (NEJM Evidence)

Singer Usher -- whose child was diagnosed with type 1 diabetes in 2014 -- to advocate for more accessible type 1 diabetes screening. (ABC News)

A federal judge ruled that Florida's new for children and adults are unconstitutional. (Reuters)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.